Navigation Links
DURECT Provides Update on CHRONOGESIC(R) Research Program

CUPERTINO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Endo Pharmaceuticals has stated that it intends to return the rights to CHRONOGESIC(R) licensed from DURECT Corporation for the U.S. and Canada. CHRONOGESIC is a product candidate consisting of a sufentanil containing implantable device intended for the treatment of moderate-to-severe chronic pain. As a result, the Development, Commercialization and Supply License Agreement between Endo and DURECT entered into in November 2002 will terminate. This return of CHRONOGESIC rights has no effect on DURECT and Endo's collaboration with respect to the sufentanil transdermal patch (TRANSDUR(TM)-Sufentanil) licensed by Endo from DURECT for the U.S. and Canada.


About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies focused on treating chronic and episodic diseases and conditions. The Company currently has multiple late-stage pharmaceutical products in development initially focused on significant unmet medical needs in pain management, with a number of research programs underway in a variety of other therapeutic areas. For more information, please visit

NOTE: CHRONOGESIC(R) and TRANSDUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. TRANSDUR-Sufentanil is a drug candidate under development and has not been submitted or approved for commercialization by the US Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statement in this press release regarding DURECT's emergence as a specialty pharmaceutical company and DURECT's product candidates are forward- looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, DURECT's (and that of its third party collaborators where applicable) abilities to obtain approvals from regulatory agencies with respect to its development activities and product candidates, design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of the product candidates, consummate collaborative agreements relating to our product candidates and technologies, manufacture and commercialize the product candidates, obtain marketplace acceptance of the product candidates and manage and obtain capital to fund its growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-K dated March 13, 2008 under the heading "Risk Factors."

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT to Participate in Cowen Annual Healthcare Conference
2. DURECT to Participate in Susquehanna Financial Healthcare Conference
3. DURECT to Present at BIO CEO Investor Conference 2008
4. DURECT to Present at 2007 BIO Investor Forum
5. DURECT to Present at UBS Global Life Sciences Conference
6. DURECT to Present at Merriman Curhan Fords Annual Investor Summit
7. LIFE Provides Medical Books and Surgical Supplies to Iraq
8. Comfort C(R) Provides Significantly Higher Absorption Than Other Leading Brand
9. Institute for Integrative Nutrition Provides Tips to Transition Bodies for Fall, Winter, Spring, Summer Eating
10. Flagship Global Health Provides 2008 Financial Guidance
11. MedPage Today(R) Provides First-Time Live Video Coverage of Medical Meeting Press Conferences
Post Your Comments:
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Dining at the University of California Berkeley, and other leading institutions in announcing ... buying power of institutions to change the way animals are raised for food. ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)...  Consumer reviews on the independent review site Consumer Affairs ... company for hearing aids, ranking it higher than Miracle Ear ... ... For Hearing Aids ... online store that provides high performance, state-of-the-art, German-engineered hearing aids directly ...
Breaking Medicine Technology: